Thailand, Philippines sign for AstraZeneca COVID-19 vaccine

Full Screen
1 / 6

James Teague, president of AstraZeneca's in Thailand attends a signing ceremony at Government House in Bangkok, Thailand Friday, Nov. 27, 2020. Thailand on Friday signed a deal to procure 26 million doses of the trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca in collaboration with Oxford University. (Chalinee Thirasupa/Pool Photo via AP)

BANGKOK – Thailand on Friday signed a $200 million deal to procure 26 million doses of a trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca in collaboration with Oxford University. It is expected to be delivered in mid-2021.

The doses would cover 13 million people in a population of about 69 million.

Thailand’s National Vaccine Institute signed a non-refundable advance market commitment contract worth 2.38 billion baht ($79 million) with AstraZeneca to reserve the supply of the vaccine candidate. Another 3.67 billion baht ($121 million) agreement for the purchase of the trial vaccine, known as AZD1222, was signed by the Health Ministry’s Disease Control Department.

“We have followed the vaccine manufacturers globally, but this group has achieved very high progress,” Thai Prime Minister Prayuth Chan-ocha said at the signing. “They are likely to be able to produce the vaccine early next year. Most importantly, we have to get ourselves ready for the domestic process including packaging and logistics.”

Government spokesperson Anucha Burapachaisri said officials are still considering how to prioritize vaccine recipients. “Those who work closely with COVID-19 patients, for example, doctors and nurses, should be among the first people. But this needs further discussion,” he said.

Oxford and AstraZeneca reported Monday that their trial vaccine appeared to be 62% effective in people who received two doses, and 90% effective when volunteers were given a half dose followed by a full dose.

They did not mention at the time, but later acknowledged, that a manufacturing issue had resulted in “a half dose of the vaccine being administered as the first dose” to some participants, a development that led to criticism that its test results were flawed.

AstraZeneca has said it plans to conduct a new global clinical trial to make a fresh assessment of the vaccine’s efficacy.